Mesothelin SS-(dsFv)-PE38
Alternative Names: Mesothelin Mab; Mesothelium Antigen Therapy - NeoPharm; SS(dsFv) PE38; SS1-PE38Latest Information Update: 11 Nov 2004
Price :
$50 *
At a glance
- Originator Unknown
- Developer National Cancer Institute (USA); NeoPharm Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Head and neck cancer; Mesothelioma; Ovarian cancer
Most Recent Events
- 31 Oct 2002 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 31 Oct 2002 Discontinued - Phase-II for Mesothelioma in USA (unspecified route)
- 31 Oct 2002 Discontinued - Preclinical for Head and neck cancer in USA (unspecified route)